Replies to post #174045 on Cytodyn Inc (CYDY)

[venus1]

quote Thank goodness there are other countries , and if our Brazil study will be as good as we think , they will give us EUA and then approval in many other places ."

misiu....just an honest question...if the philippinews did NOT embrace cydy.....for whatever reason......who knows why...what makes you think Brazil will come around.....if the philipines did NOT embrace cydy ....what country will?

just wondering.....

[Emergcy]

Great summary of our situation.

Let's continue dying people on HIV and COVID, if not from the disease, then from the drug's side effects. Let's continue to destroy economies, let's get high inflation because of trillions of $ pumped into the sick economies to keep it alive, let's continue the behaviour of the societies, let's continue to suck out from people the Pharma- Dollars.

US- pharma built the perfect system to control Congress, governments and media across the world.

Look at Switzerland, which runs currently a voting across the country to stop money given from the industry to the media as; they say there is no free press anymore; bribes control the press (they call it subsidies).

As long as pharma subsidies to the extent of about 45% of FDA's budget, as long they support clinics and universities, there is no independent regulator, no independent research and no treatment in hospitals in the interest of patients.

[3X Charm]

Misiu. All due respect. Nader admitted in the ProActive Video last week that the RTF was due to a poor submission report by CYDY and poor RO analysis and dosing report.

This also substantiates my prior claims that RO was always known by Cydy; it was in the BLA, contrary to claims it was added later by FDA.

This video contradicts all NP’s prior comments on the failure of the HIV BLA.

He has also ALWAYS said FDA has been very helpful and for people to basically get off FDA’s back.

Was/is NP lying about all of this regarding the FDA?

If FDA was being obstructive, why would Nader constantly lie about this, and complement , instead of just Never Commenting on FDA?

He gets no extra credit to complement FDA, they could care less about a Nader complement. They do care when he lies about trial results and they said so in a very public PR.

There has never been 3rd party confirmation on these type of claims regarding FDA changing things. In fact these claims regarding HIV are completely repudiated by Nader last week.

Is NP practicing his lying or just lying because that is what he does? Or has he always been telling the truth about FDA? One of these comments is true.

I know It is difficult to follow due to all the other lies.

[stockorus]

What happens to our BLA and approval for HIV if FDA approves the Gilesd capcid drug first? Will we still have the same chance at approval based on our corrected BLA?

If we are now competing against Gilead’s capcid inhibitor, how did that drug perform in its phase 3 trials compared to LL?

Finally this person tweets that 2/3 of blood samples from our trials were not saved, hence we cannot do the ROT now? Is this true and how then might Dr. Recknor fix this? Somebody can mail him and ask on this.

Yes, I recently learned this as well. The main issue is that a previous lab, before InCellDx, did not save blood on 2/3 of cases. You can’t do ROT! Rather you need a scientist such as Dr Patterson to work w FDA on alternate options for HIV BLA approval. @brucep13

— Donna (@Anonymous_0004) July 8, 2021

[ClosetInvestor]

“So FDA worked VERY hard to delay our approval for 3 1/2 years now , until Gilead is ready.”

Have you ever considered that Gilead may have reached out to CYDY for an HIV partnership and NP turned that opportunity away for Vyera? I think that’s a real possibility because the leronlimab combo trial was so successful. But going with Vyera didn’t provide the benefit that a partnership with Gilead would’ve offered. Instead, with Vyera, we’re not 3 years behind the combo HIV market and Gilead has caught up. Sure, the company would’ve only got 20% of the cut, but leronlimab would’ve been on the market for combo in 2019/2020, mono would be on track for approval, and that 20% could be funding more trials.